Protein C News and Research

RSS

Researchers aim to better understand clinical features associated with COVID-19 mortality

To better understand the COVID-19 clinical feaures associated with mortality, an interdisciplinary team of researchers has investigated important factors and their influence on a patient’s death.

22 Apr 2021

Researchers examine if a naturally occurring protein can be used to prevent sight loss from glaucoma

Researchers funded by Fight for Sight, in partnership with The Spectacle Makers’ Charity and Glaucoma UK, are investigating if a naturally occuring protein in the body can be used to prevent sight loss from glaucoma.

22 Apr 2021

Gene-regulatory mechanisms at an early embryonic stage govern the flowering behavior of Arabidopsis

Researchers at GMI - Gregor Mendel Institute of Molecular Plant Biology of the Austrian Academy of Sciences - and the John Innes Centre, Norwich, United Kingdom, determine that gene-regulatory mechanisms at an early embryonic stage govern the flowering behavior of Arabidopsis later in development. The paper is published in the journal PNAS.

22 Apr 2021

Metabolic testing of COVID-19 patients through skin imprints

There is, therefore, a great need to understand how the illness can be diagnosed using more convenient and inexpensive methods. A new study posted to the medRxiv preprint server reveals the potential role of skin imprints to test for biomarkers that indicate a diagnosis of COVID-19 in a non-invasive way.

22 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Collaborative research could expedite or eliminate the need to manually adjust bioproduction process

Much of common pharmaceutical development today is the product of laborious cycles of tweaking and optimization.

21 Apr 2021

Novel approach to gene editing bypasses disease-causing mutations in a gene

A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases.

21 Apr 2021

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world.

21 Apr 2021

Researchers discover how SARS viruses enhance the production of viral proteins in infected cells

Coronavirus researchers led by Professor Rolf Hilgenfeld of the University of Luebeck and PD Dr. Albrecht von Brunn of the Ludwig-Maximilian Universitaet in Munich have discovered how SARS viruses enhance the production of viral proteins in infected cells, so that many new copies of the virus can be generated.

21 Apr 2021

Animal study shows how chemical compound in Indian Long Pepper works against glioblastoma

Piperlongumine, a chemical compound found in the Indian Long Pepper plant (Piper longum), is known to kill cancerous cells in many tumor types, including brain tumors.

21 Apr 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

SARS-CoV-1 utilizes ORF3a protein to trigger viral release

Scientists in the USA – from the Johns Hopkins University and the University of Maryland – have recently uncovered the mechanism by which SARS-CoV-1 is released from the infected cells.

21 Apr 2021

Georgia State professor receives $2.3 million federal grant to study inflammation in infectious diseases

Dr. Jian-Dong Li, professor and director of the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.3 million federal grant to study how overactive inflammatory response is caused in infectious diseases and to further develop novel anti-inflammatory therapeutics.

21 Apr 2021

What do we know about the origin and evolution of SARS-CoV-2?

A new study examines the origin and continuing evolution of SARS-CoV-2 in the human and animal co-hosts in an attempt to help prepare for future destructive outbreaks.

21 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

Researchers explore cost-effective identification method for novel SARS-CoV-2 variants

In a new study, a rapid and cost-effective method of detecting known variants of concern has been developed utilizing capillary electrophoresis, allowing local facilities to screen for and track SARS-CoV-2 variants of concern and implement reactionary procedures.

21 Apr 2021

Researchers examine antiviral responses in children infected with COVID-19 in South Brazil

New research has been published that focuses on the characterization of innate and adaptive immune responses in adult patients with different degrees of severity and also in pediatric patients with mild symptoms of COVID-19. In this study, researchers have developed an immune profile in children to understand the difference in COVID-19 infection in children and adults.

21 Apr 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Protein C News and Research

Researchers aim to better understand clinical features associated with COVID-19 mortality

Researchers examine if a naturally occurring protein can be used to prevent sight loss from glaucoma

Gene-regulatory mechanisms at an early embryonic stage govern the flowering behavior of Arabidopsis

Metabolic testing of COVID-19 patients through skin imprints

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Collaborative research could expedite or eliminate the need to manually adjust bioproduction process

Novel approach to gene editing bypasses disease-causing mutations in a gene

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Researchers discover how SARS viruses enhance the production of viral proteins in infected cells

Animal study shows how chemical compound in Indian Long Pepper works against glioblastoma

Interfering RNA nanoparticles could be a potential COVID-19 therapy

SARS-CoV-1 utilizes ORF3a protein to trigger viral release

Georgia State professor receives $2.3 million federal grant to study inflammation in infectious diseases

What do we know about the origin and evolution of SARS-CoV-2?

Immune escape by SARS-CoV-2 mutations acquired in mink

Researchers explore cost-effective identification method for novel SARS-CoV-2 variants

Researchers examine antiviral responses in children infected with COVID-19 in South Brazil

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News